New drug combo aims to outsmart tough lung cancer

This study is testing if adding a new drug called SYS6010 to a standard lung cancer drug (osimertinib) works better for controlling advanced non-small cell lung cancer with specific genetic changes (EGFR mutations). About 450 adults who haven't yet received treatment for their advanced cancer will be randomly assigned to get either the combination or the standard drug alone. The main goal is to see if the combination keeps the cancer from growing for a longer time.